Organ and tumor dosimetry of [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC
Terbium-161 (161Tb) has emerged as a promising radionuclide for radioligand therapy (RLT) due to its emission of Auger and conversion electrons, which may support therapeutic efficacy through increased local energy deposition. Despite growing research efforts aimed at the clinical potential of 161Tb, dosimetric data, p...